Last €30.89 EUR
Change Today +0.314 / 1.03%
Volume 0.0
CDG On Other Exchanges
As of 11:21 AM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (CDG) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/11/14 - €31.74
52 Week Low
01/7/14 - €20.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acorda therapeutics inc (CDG) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (CDG) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company’s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications. The company was founded in 1995 and is headquartered in Ardsley, New York.

421 Employees
Last Reported Date: 03/3/14
Founded in 1995

acorda therapeutics inc (CDG) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $720.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $193.9K
Chief of Business Operations
Total Annual Compensation: $312.7K
General Counsel, Corporate Secretary and Pres...
Total Annual Compensation: $517.7K
Chief Medical Officer
Total Annual Compensation: $418.5K
Compensation as of Fiscal Year 2013.

acorda therapeutics inc (CDG) Key Developments

Acorda Therapeutics, Inc. Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits

Acorda Therapeutics, Inc.  announced that the first patient has been enrolled in a Phase 3 clinical trial of dalfampridine for the treatment of post-stroke walking deficits (PSWD). This multi-center, double-blind, randomized trial is expected to enroll approximately 540 participants who have experienced an ischemic stroke at least six months prior to enrollment. Participants will receive 10 mg dalfampridine, 7.5 mg dalfampridine, or placebo twice daily for 12 weeks. The primary endpoint of the study is the percentage of patients taking dalfampridine who demonstrate at least a 20% improvement in the 2 Minute Walk Test (2MinWT) compared to those receiving placebo. The 2MinWT measures the distance a person can walk in 2 minutes. Other measures will include the Timed Up and Go, which assesses mobility and balance, as well as clinician and patient-reported measures. The study also includes evaluation of safety and tolerability.

Acorda Therapeutics, Inc. Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease

Acorda Therapeutics, Inc. announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episodes are characterized by a re-emergence of PD symptoms such as tremor, muscle stiffness and impaired ability to move. CVT-301 is a novel, self-administered inhaled therapy designed to provide rapid, reliable delivery of a precise dose of levodopa (L-dopa) through the lungs to return people with PD to an ON state. An ON state is when a patients symptoms are adequately controlled, allowing people with Parkinson's to more readily perform daily activities. The multi-center, double blind, randomized trial is expected to enroll approximately 345 participants across three arms: 50mg, 35mg, or placebo. These are the same doses used in the Phase 2b study. The primary outcome measure is improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) Part III after administration of CVT-301.

Acorda Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:00 AM

Acorda Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Andrew R. Blight, Chief Scientific Officer, Michael W. Rogers, Chief Financial Officer and Principal Accounting Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDG:GR €30.89 EUR +0.314

CDG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $31.50 USD +1.48
Avanir Pharmaceuticals Inc $16.92 USD +0.01
Depomed Inc $15.26 USD +0.51
Durect Corp $0.87 USD +0.0475
Isis Pharmaceuticals Inc $57.48 USD +2.54
View Industry Companies

Industry Analysis


Industry Average

Valuation CDG Industry Range
Price/Earnings 69.0x
Price/Sales 4.2x
Price/Book 3.0x
Price/Cash Flow 68.4x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at